Publications
Below you can find a list of our published research.
Below you can find a list of our published research.
509 results
Cited 9 times since 2021 (3.7 per year) source: EuropePMC
Future oncology (London, England), Volume 18, Issue 7, 17 3 2021, Pages 781-791 Encorafenib plus binimetinib in patients with <i>BRAF</i><sup>V600</sup>-mutant non-small cell lung cancer: phase II PHAROS study design. Riely GJ, Ahn MJ, Felip E, Ramalingam SS, Smit EF, Tsao AS, Alcasid A, Usari T, Wissel PS, Wilner KD, Johnson BE
BRAFV600 oncogenic driver mutations occur in 1-2% of non-small-cell lung cancers (NSCLCs) and have been shown to be a clinically relevant target. Preclinical/clinical evidence support the efficacy and safety of BRAF and MEK inhibitor combinations in patients with NSCLC with these mutations. We describe the design of PHAROS, an ongoing, open-label, single-arm, phase II trial evaluating the BRAF inhibitor encorafenib plus the MEK inhibitor binimetinib in patients with metastatic BRAFV600-mutant NS... Abstract
Cited 2 times since 2021 (0.8 per year) source: EuropePMC
Drugs, Volume 82, Issue 1, 11 2 2021, Pages 15-32 Optimized Dosing: The Next Step in Precision Medicine in Non-Small-Cell Lung Cancer. Boosman RJ, Burgers JA, Smit EF, Steeghs N, van der Wekken AJ, Beijnen JH, Huitema ADR, Ter Heine R
In oncology, and especially in the treatment of non-small-cell lung cancer (NSCLC), dose optimization is often a neglected part of precision medicine. Many drugs are still being administered in "one dose fits all" regimens or based on parameters that are often only minor determinants for systemic exposure. These dosing approaches often introduce additional pharmacokinetic variability and do not add to treatment outcomes. Fortunately, pharmacological knowledge is increasing, providing v... Abstract
Cited 1 times since 2021 (0.4 per year) source: EuropePMC
Targeted oncology, Volume 17, Issue 1, 11 2 2021, Pages 53-59 Representativeness of Phase III Trial for Osimertinib in Pretreated Advanced EGFR-Mutated Non-small-cell Lung Cancer Patients and Treatment Outcomes in Clinical Practice. Lin L, Smit EF, de Langen AJ, van Balen DEM, Beijnen JH, Huitema ADR
Background: Overall survival (OS) data of osimertinib in pretreated non-small-cell lung cancer (NSCLC) in real-world practice is limited, and treatment benefits for patients not represented in the pivotal trials (ineligible) are unclear. Objective: To determine the representativeness of the AURA3 trial for NSCLC patients treated with osimertinib in a real-world setting and to determine outcomes of patients who were represented in the AURA3 trial (eligible) and those who were ineligible. Methods:... Abstract
Cited 95 times since 2021 (37.7 per year) source: EuropePMC
The Lancet. Oncology, Volume 22, Issue 12, 9 2 2021, Pages 1681-1691 mRNA-1273 COVID-19 vaccination in patients receiving chemotherapy, immunotherapy, or chemoimmunotherapy for solid tumours: a prospective, multicentre, non-inferiority trial. Oosting SF, van der Veldt AAM, GeurtsvanKessel CH, Fehrmann RSN, van Binnendijk RS, Dingemans AC, Smit EF, Hiltermann TJN, den Hartog G, Jalving M, Westphal TT, Bhattacharya A, van der Heiden M, Rimmelzwaan GF, Kvistborg P, Blank CU, Koopmans MPG, Huckriede ALW, van Els CACM, Rots NY, van Baarle D, Haanen JBAG, de Vries EGE
Background: Patients with cancer have an increased risk of complications from SARS-CoV-2 infection. Vaccination to prevent COVID-19 is recommended, but data on the immunogenicity and safety of COVID-19 vaccines for patients with solid tumours receiving systemic cancer treatment are scarce. Therefore, we aimed to assess the impact of immunotherapy, chemotherapy, and chemoimmunotherapy on the immunogenicity and safety of the mRNA-1273 (Moderna Biotech, Madrid, Spain) COVID-19 vaccine as part of th... Abstract
Cited 2 times since 2021 (0.8 per year) source: EuropePMC
JTO clinical and research reports, Volume 2, Issue 12, 1 1 2021, Pages 100252 Real-World Approach for Molecular Analysis of Acquired EGFR Tyrosine Kinase Inhibitor Resistance Mechanisms in NSCLC. Hondelink LM, Jebbink M, von der Thüsen JH, Cohen D, Dubbink HJ, Paats MS, Dingemans AC, de Langen AJ, Boelens MC, Smit EF, Postmus PE, van Wezel T, Monkhorst K
Introduction: With the approval of first-line osimertinib treatment in stage IV EGFR-mutated NSCLC, detection of resistance mechanisms will become increasingly important-and complex. Clear guidelines for analyses of these resistance mechanisms are currently lacking. Here, we provide our recommendations for optimal molecular diagnostics in the post-EGFR tyrosine kinase inhibitor (TKI) resistance setting. Methods: We compared molecular workup strategies from three hospitals of 161 first- or second... Abstract
Cited 1 times since 2021 (0.4 per year) source: EuropePMC
Lung cancer (Amsterdam, Netherlands), Volume 161, 27 4 2021, Pages 141-151 The role of surgery in the treatment of oligoprogression after systemic treatment for advanced non-small cell lung cancer. Joosten PJM, de Langen AJ, van der Noort V, Monkhorst K, Klomp HM, Veenhof AAFA, Dickhoff C, Smit EF, Hartemink KJ
Objectives: Patients with advanced stage non-small cell lung cancer (NSCLC) are generally considered incurable. The mainstay of treatment for these patients is systemic therapy. The addition of local treatment, including surgery, remains controversial. Oligoprogression is defined as advanced stage NSCLC with limited progression of disease after a period of prolonged disease stabilisation or after a partial or complete response on systemic therapy. In this retrospective study we evaluated outcome... Abstract
Cited 244 times since 2021 (91.6 per year) source: EuropePMC
The New England journal of medicine, Volume 386, Issue 3, 18 3 2021, Pages 241-251 Trastuzumab Deruxtecan in <i>HER2</i>-Mutant Non-Small-Cell Lung Cancer. Li BT, Smit EF, Goto Y, Nakagawa K, Udagawa H, Mazières J, Nagasaka M, Bazhenova L, Saltos AN, Felip E, Pacheco JM, Pérol M, Paz-Ares L, Saxena K, Shiga R, Cheng Y, Acharyya S, Vitazka P, Shahidi J, Planchard D, Jänne PA, DESTINY-Lung01 Trial Investigators
Background: Human epidermal growth factor receptor 2 (HER2)-targeted therapies have not been approved for patients with non-small-cell lung cancer (NSCLC). The efficacy and safety of trastuzumab deruxtecan (formerly DS-8201), a HER2 antibody-drug conjugate, in patients with HER2-mutant NSCLC have not been investigated extensively. Methods: We conducted a multicenter, international, phase 2 study in which trastuzumab deruxtecan (6.4 mg per kilogram of body weight) was administered to patients who... Abstract
Clinical pharmacology and therapeutics, Volume 110, Issue 5, 13 2 2021, Pages 1164 Response to "Optimized Alectinib Dose Regimen for Treatment of Patients With ALK-Positive NSCLC Based on Robust Pharmacometric Analyses and Clinical Evidence". Groenland SL, Geel DR, Beijnen JH, Smit EF, Huitema ADR, Steeghs N
Cited 27 times since 2021 (9.8 per year) source: EuropePMC
Journal of nuclear medicine : official publication, Society of Nuclear Medicine, Volume 63, Issue 5, 12 2 2021, Pages 686-693 PD-L1 PET/CT Imaging with Radiolabeled Durvalumab in Patients with Advanced-Stage Non-Small Cell Lung Cancer. Smit J, Borm FJ, Niemeijer AN, Huisman MC, Hoekstra OS, Boellaard R, Oprea-Lager DE, Vugts DJ, van Dongen GAMS, de Wit-van der Veen BJ, Thunnissen E, Smit EF, de Langen AJ
Better biomarkers are needed to predict treatment outcome in non-small cell lung cancer (NSCLC) patients treated with anti-programmed death-1/programmed death-ligand 1 (PD-1/PD-L1) checkpoint inhibitors. PD-L1 immunohistochemistry has limited predictive value, possibly because of tumor heterogeneity of PD-L1 expression. Noninvasive PD-L1 imaging using 89Zr-durvalumab might better reflect tumor PD-L1 expression. Methods: NSCLC patients eligible for second-line immunotherapy were enrolled. Patient... Abstract
Cited 23 times since 2021 (8.3 per year) source: EuropePMC
Nature medicine, Volume 27, Issue 9, 9 2 2021, Pages 1553-1563 Limited evolution of the actionable metastatic cancer genome under therapeutic pressure. van de Haar J, Hoes LR, Roepman P, Lolkema MP, Verheul HMW, Gelderblom H, de Langen AJ, Smit EF, Cuppen E, Wessels LFA, Voest EE
Genomic profiling is critical for the identification of treatment options for patients with metastatic cancer, but it remains unclear how frequently this procedure should be repeated during the course of the disease. To address this, we analyzed whole-genome sequencing (WGS) data of 250 biopsy pairs, longitudinally collected over the treatment course of 231 adult patients with a representative variety of metastatic solid malignancies. Within the biopsy interval (median, 6.4 months), patients rec... Abstract
Cited 1 times since 2021 (0.4 per year) source: EuropePMC
Lung cancer (Amsterdam, Netherlands), Volume 160, 4 1 2021, Pages 44-49 Randomized phase III study of docetaxel versus docetaxel plus intercalated erlotinib in patients with relapsed non-squamous non-small cell lung carcinoma. Steendam CMJ, Peric R, van Walree NC, Youssef M, Schramel FMNH, Brocken P, van Putten JWG, van der Noort V, Veerman GDM, Koolen SLW, Groen HJM, Dingemans AC, Mathijssen RHJ, Smit EF, Aerts JGJV, NVALT Study Group
Background: Earlier preclinical and phase II research showed enhanced effect of docetaxel plus intercalated erlotinib. The NVALT-18 phase III study was designed to compare docetaxel with docetaxel plus intercalated erlotinib in relapsed metastasized non-squamous (NSQ) non-small cell lung cancer (NSCLC). Methods: Patients with relapsed Epidermal Growth Factor Receptor (EGFR) wild type (WT) NSQ-NSCLC were randomized 1:1 to docetaxel 75 mg/m2 intravenously on day 1 every 21 days (control), or docet... Abstract
Journal of thoracic oncology : official publication of the International Association for the Study of Lung Cancer, Volume 16, Issue 8, 1 1 2021, Pages 1242-1243 Concurrent Chemoradiation, Adjuvant Durvalumab, and KEAP-1/NRF-2 Mutations: A Happy Marriage? Smit EF, Belderbos J
Cited 27 times since 2021 (9.5 per year) source: EuropePMC
Journal of nuclear medicine : official publication, Society of Nuclear Medicine, Volume 63, Issue 3, 16 3 2021, Pages 362-367 Study of <sup>89</sup>Zr-Pembrolizumab PET/CT in Patients With Advanced-Stage Non-Small Cell Lung Cancer. Niemeijer AN, Oprea-Lager DE, Huisman MC, Hoekstra OS, Boellaard R, de Wit-van der Veen BJ, Bahce I, Vugts DJ, van Dongen GAMS, Thunnissen E, Smit EF, de Langen AJ
The tumor programmed death ligand 1 (PD-L1) proportion score is the current method for selecting non-small cell lung cancer (NSCLC) patients for single-agent treatment with pembrolizumab, a programmed cell death 1 (PD-1) monoclonal antibody. However, not all patients respond to therapy. Better understanding of in vivo drug behavior may help in the selection of patients who will benefit the most. Methods: NSCLC patients eligible for pembrolizumab monotherapy as first- or later-line therapy were e... Abstract
Cited 8 times since 2021 (2.8 per year) source: EuropePMC
Lung cancer (Amsterdam, Netherlands), Volume 159, 16 3 2021, Pages 96-106 Real-world insights into patients with advanced NSCLC and MET alterations. Bittoni M, Yang JC, Shih JY, Peled N, Smit EF, Camidge DR, Arasada RR, Oksen D, Boutmy E, Stroh C, Johne A, Carbone DP, Paik PK
Objectives: To describe characteristics, treatment and outcomes of non-small cell lung cancer (NSCLC) patients with MET alterations (MET exon 14 [METex14] skipping or MET amplification [METamp]) in real-world clinical care. Methods: This non-interventional cohort study used real-world data extracted from electronic medical records from academic oncology sites in Israel, The Netherlands, Taiwan, and the USA. Patients had confirmed diagnosis of advanced (Stage IIIB-IV) NSCLC harboring MET alterati... Abstract
Cited 8 times since 2021 (2.8 per year) source: EuropePMC
Cancers, Volume 13, Issue 12, 21 3 2021, Pages 3083 Response Prediction and Evaluation Using PET in Patients with Solid Tumors Treated with Immunotherapy. Borm FJ, Smit J, Oprea-Lager DE, Wondergem M, Haanen JBAG, Smit EF, de Langen AJ
In multiple malignancies, checkpoint inhibitor therapy has an established role in the first-line treatment setting. However, only a subset of patients benefit from checkpoint inhibition, and as a result, the field of biomarker research is active. Molecular imaging with the use of positron emission tomography (PET) is one of the biomarkers that is being studied. PET tracers such as conventional 18F-FDG but also PD-(L)1 directed tracers are being evaluated for their predictive power. Furthermore,... Abstract
Cited 42 times since 2021 (13.4 per year) source: EuropePMC
Nature medicine, Volume 27, Issue 4, 1 1 2021, Pages 568-569 COVID-19 vaccination: the VOICE for patients with cancer. van der Veldt AAM, Oosting SF, Dingemans AC, Fehrmann RSN, GeurtsvanKessel C, Jalving M, Rimmelzwaan GF, Kvistborg P, Blank CU, Smit EF, Lemmens VEEP, Hiltermann TJN, Koopmans MPG, Huckriede ALW, Rots NY, van Els CACM, van Baarle D, Haanen JBAG, de Vries EGE
Cited 6 times since 2021 (1.9 per year) source: EuropePMC
Lung cancer (Amsterdam, Netherlands), Volume 155, 26 4 2021, Pages 156-162 Identifying advanced stage NSCLC patients who benefit from afatinib therapy using <sup>18</sup>F-afatinib PET/CT imaging. van de Stadt EA, Yaqub M, Lammertsma AA, Poot AJ, Schuit RC, Remmelzwaal S, Schwarte LA, Smit EF, Hendrikse H, Bahce I
Objectives: Non-small cell lung cancer (NSCLC) tumors harboring common (exon19del, L858R) and uncommon (e.g. G719X, L861Q) activating epidermal growth factor receptor (EGFR) mutations are best treated with EGFR tyrosine kinase inhibitors (TKI) such as the first-generation EGFR TKI erlotinib, second-generation afatinib or third-generation osimertinib. However, identifying these patients through biopsy is not always possible. Therefore, our aim was to evaluate whether 18F-afatinib PET/CT could ide... Abstract
Cited 17 times since 2021 (5.3 per year) source: EuropePMC
Frontiers in oncology, Volume 11, 2 1 2021, Pages 609054 Prognostic Value of Deep Learning-Mediated Treatment Monitoring in Lung Cancer Patients Receiving Immunotherapy. Trebeschi S, Bodalal Z, Boellaard TN, Tareco Bucho TM, Drago SG, Kurilova I, Calin-Vainak AM, Delli Pizzi A, Muller M, Hummelink K, Hartemink KJ, Nguyen-Kim TDL, Smit EF, Aerts HJWL, Beets-Tan RGH
Background: Checkpoint inhibitors provided sustained clinical benefit to metastatic lung cancer patients. Nonetheless, prognostic markers in metastatic settings are still under research. Imaging offers distinctive advantages, providing whole-body information non-invasively, while routinely available in most clinics. We hypothesized that more prognostic information can be extracted by employing artificial intelligence (AI) for treatment monitoring, superior to 2D tumor growth criteria. Methods: A... Abstract
Cited 12 times since 2021 (3.7 per year) source: EuropePMC
Cancer treatment reviews, Volume 95, 1 1 2021, Pages 102173 Capmatinib for patients with non-small cell lung cancer with MET exon 14 skipping mutations: A review of preclinical and clinical studies. Wu YL, Smit EF, Bauer TM
The mesenchymal-epithelial transition (MET) receptor tyrosine kinase binds the hepatocyte growth factor to activate downstream cell signaling pathways involved in cell proliferation, survival, and migration. Several genetic mechanisms can result in an aberrant activation of this receptor in cancer cells. One such activating mechanism involves the acquisition of gene mutations that cause MET exon 14 skipping (METex14) during mRNA splicing. Mutations leading to METex14 are found in approximately 3... Abstract
Cited 6 times since 2021 (1.9 per year) source: EuropePMC
Journal of thoracic oncology : official publication of the International Association for the Study of Lung Cancer, Volume 16, Issue 3, 1 1 2021, Pages 355-365 Lung Cancer in the Netherlands. Hendriks LEL, Dingemans AC, De Ruysscher DKM, Aarts MJ, Barberio L, Cornelissen R, Hartemink KJ, van den Heuvel M, Schuuring E, Smit HJM, van der Wekken AJ, Smit EF